Cytokinetics Statistics
Cytokinetics (KK3A) Stock Statistics & Valuation Metrics
Total Valuation
Cytokinetics has a market cap or net worth of EUR 6.66B. The enterprise value is EUR 9.30B.
- Market Cap
- EUR 6.66B
- Enterprise Value
- EUR 9.30B
Share Statistics
Cytokinetics has 139,303,340 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 139,303,340
- Owned by Insiders
- 0.63%
- Owned by Institutions
- 66.93%
Financial Efficiency
Cytokinetics’s return on equity (ROE) is 1.19 and return on invested capital (ROIC) is -47.74%.
- Return on Equity (ROE)
- 1.19
- Return on Assets (ROA)
- -0.55
- Return on Invested Capital (ROIC)
- -47.74%
- Return on Capital Employed (ROCE)
- -0.50
- Revenue Per Employee
- 130.82K
- Profits Per Employee
- -1.17M
- Employee Count
- 673
- Asset Turnover
- 0.06
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Cytokinetics is -9.32. Cytokinetics’s PEG ratio is -9.21.
- PE Ratio
- -9.32
- PS Ratio
- 68.94
- PB Ratio
- -24.32
- Price to FCF
- -13.27
- Price to Operating Cash Flow
- -13.66
- PEG Ratio
- -9.21
Income Statement
In the last 12 months, Cytokinetics had revenue of 88.04M and earned -784.96M in profits. Earnings per share was -6.54.
- Revenue
- 88.04M
- Gross Profit
- 77.91M
- Operating Income
- -612.26M
- Pretax Income
- -784.96M
- Net Income
- -784.96M
- EBITDA
- -774.83M
- Earnings Per Share (EPS)
- -6.54
Cash Flow
In the last 12 months, operating cash flow was -571.97M and capital expenditures -16.61M, giving a free cash flow of -588.58M billion.
- Operating Cash Flow
- -571.97M
- Free Cash Flow
- -588.58M
- Free Cash Flow per Share
- -4.23
Dividends & Yields
Cytokinetics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -7.73%
- Earnings Yield
- -10.21%
Stock Price Statistics
- Beta
- 0.14
- 52-Week Price Change
- -8.84%
- 50-Day Moving Average
- 58.05
- 200-Day Moving Average
- 60.78
- Relative Strength Index (RSI)
- 31.23
- Average Volume (3m)
- 118
Important Dates
Cytokinetics upcoming earnings date is Mar 02, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Mar 02, 2027
- Ex-Dividend Date
- ―
Financial Position
Cytokinetics as a current ratio of 4.53, with Debt / Equity ratio of -194.69%
- Current Ratio
- 4.53
- Quick Ratio
- 4.53
- Debt to Market Cap
- 0.15
- Net Debt to EBITDA
- -1.50
- Interest Coverage Ratio
- -5.89
Taxes
In the past 12 months, Cytokinetics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Cytokinetics EV to EBITDA ratio is -12.55, with an EV/FCF ratio of -14.76.
- EV to Sales
- 76.69
- EV to EBITDA
- -12.55
- EV to Free Cash Flow
- -14.76
- EV to Operating Cash Flow
- -15.19
Balance Sheet
Cytokinetics has EUR 1.13B in cash and marketable securities with EUR 1.27B in debt, giving a net cash position of -EUR 142.54M billion.
- Cash & Marketable Securities
- EUR 1.13B
- Total Debt
- EUR 1.27B
- Net Cash
- -EUR 142.54M
- Net Cash Per Share
- -EUR 1.02
- Tangible Book Value Per Share
- -EUR 2.31
Margins
Gross margin is 91.00%, with operating margin of -625.15%, and net profit margin of -686.63%.
- Gross Margin
- 91.00%
- Operating Margin
- -625.15%
- Pretax Margin
- -686.63%
- Net Profit Margin
- -686.63%
- EBITDA Margin
- -611.31%
- EBIT Margin
- -623.24%
Analyst Forecast
The average price target for Cytokinetics is EUR 95.77, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 95.77
- Price Target Upside
- 96.37% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 17
- Revenue Growth Forecast
- 25.43%
- EPS Growth Forecast
- 8.23%
Scores
- Smart Score
- 9
- AI Score
- ―
